Get the Stockscreener App
6.94
1.02%
0.07
Pre-market:
7.26
0.32
+4.61%
Kala Bio Inc stock is traded at $6.94, with a volume of 30,129.
It is up +1.02% in the last 24 hours and up +1.20% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$6.87
Open:
$6.89
24h Volume:
30,129
Relative Volume:
1.12
Market Cap:
$31.99M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-99.14
EPS:
-0.07
Net Cash Flow:
$-32.63M
1W Performance:
+11.22%
1M Performance:
+1.20%
6M Performance:
-2.12%
1Y Performance:
-0.86%
1-Day Range:
$6.52
$7.2007
1-Week Range:
$6.2401
$7.32
52-Week Range:
$4.21
$9.25
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
6.94 | 31.99M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.70 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
712.33 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
615.00 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.31 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.95 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
KALA BIO announces $10.75M private placement - MSN
Baker Bros. Advisors buys $2 million in Kala Bio shares By Investing.com - Investing.com Nigeria
Baker Bros. Advisors buys $2 million in Kala Bio shares - Investing.com
Kala Bio raises $10.75 million in private placement By Investing.com - Investing.com Canada
KALA BIO Announces Private Placement Agreement with Institutional Investors - Defense World
KALA BIO Secures $10.75 Million in Private Placement to Advance Eye Disease Treatments - Tandav Media
Kala Bio raises $10.75 million in private placement - Investing.com India
KALA Bio Secures $10.75 Million for Eye Disease Treatments: What’s Next for the Biopharma Stock? - Tandav Media
KALA BIO Announces $10,750,000 Private Placement - GlobeNewswire
Global Engine Group Holding Limited Acquires 22.5% Stake in Corpotech Holdings Limited, a Hong Kong Data Centre Operator - The Manila Times
KALA BIO Secures $10.75M Investment from Major Funds, Extends Cash Runway for Key Eye Treatment Trial - StockTitan
BioAtla announces registered direct offering to advance two mid-stage clinical programs, shares fall - Seeking Alpha
KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Zacks Investment Research
Kala Bio (LTS:0JQ2) EV-to-Revenue : (As of Nov. 30, 2024) - GuruFocus.com
KALAKALA BIO, Inc. Latest Stock News & Market Updates - StockTitan
FTC Solar Announces Reverse Stock Split - The Manila Times
KALA BIO to Present at Piper Sandler Healthcare Conference, Showcasing Eye Disease Pipeline | KALA Stock News - StockTitan
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
2024 Pharmaceutical Executive APEX Award Winners - Pharmaceutical Executive
Kala Pharmaceuticals Announces IND Submission of its MPP-Formulated Loteprednol Etonbonate (LE-MPP) for Post-Cataract Surgery - Marketscreener.com
Kala Pharmaceuticals retains stock target with Buy rating on trial progress - Investing.com India
60 Degrees Pharmaceuticals’ (SXTP) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Walt Disney (NYSE:DIS) Price Target Raised to $130.00 - Defense World
KALA BIO’s (KALA) Buy Rating Reaffirmed at HC Wainwright - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kala Bio Inc - GuruFocus.com
KALA BIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kala Bio Advances PCED Treatment Amid Financial Update - TipRanks
KALA BIO: Q3 Earnings Snapshot - mySA
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
KALA BIO Reports $49.2M Cash Position, Advances Phase 2b PCED Trial Despite Wider Losses | KALA Stock News - StockTitan
Super Micro slumps as weak forecast, annual report uncertainty fuel investor angst - AOL
Standard Life Private Equity Trust (LON:SLPE) Trading Down 1.5% – Here’s Why - Defense World
Travis Kalanick | Biography, Uber, & Facts - Britannica
Persistent Corneal Epithelial Defects Pipeline 2024: Clinical - openPR
Persistent Epithelial Defect Market Size is Set for Rapid Growth - openPR
Sunrun (NASDAQ:RUN) Trading Down 5.8% on Insider Selling - Defense World
MPTI Stock Trades Near 52-Week High: Is It Still Worth Buying? - MSN
Here's What Makes Cabot Stock a Solid Choice Right Now - MSN
Here's Why Welltower Stock is an Apt Portfolio Pick for Now - MSN
Broadcom Stock Hits Buy Point On Product News Ahead Of Major Conference - MSN
KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade - Yahoo Finance
Dynatrace Shows Improved Relative Strength; Still Shy Of Benchmark - MSN
Brookdale Bets Big With $610M Acquisitions Amid Debt Refinancing - MSN
Toast, Inc. (TOST) is Attracting Investor Attention: Here is What You Should Know - MSN
Here's Why Freeport-McMoRan Stock Soared in September - AOL
Oppenheimer Initiates Coverage of Euronet Worldwide (EEFT) with Outperform Recommendation - MSN
Transparency-One’s Kala Hanson Named Recipient of 2024 Women in Supply Chain Award - Yahoo Finance
AAM Names John A. Murphy as CEO - Pharmaceutical Executive
KALA BIO director resigns from board and committees By Investing.com - Investing.com Australia
KALA BIO director resigns from board and committees - Investing.com
Kala Pharmaceuticals Board Member Mark Blumenkranz Resigns - TipRanks
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bazemore Todd | SEE REMARKS |
Jun 26 '24 |
Sale |
4.75 |
4,653 |
22,102 |
83,040 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
Jun 26 '24 |
Sale |
4.75 |
5,158 |
24,500 |
59,728 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jun 26 '24 |
Sale |
4.75 |
4,163 |
19,774 |
60,187 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
Jun 26 '24 |
Sale |
4.75 |
15,168 |
72,048 |
263,755 |
| Brazzell Romulus K | SEE REMARKS |
Jun 26 '24 |
Sale |
4.75 |
5,489 |
26,073 |
83,982 |
| Bazemore Todd | SEE REMARKS |
May 31 '24 |
Sale |
6.09 |
2,093 |
12,746 |
87,693 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
May 31 '24 |
Sale |
6.09 |
231 |
1,407 |
64,886 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
May 31 '24 |
Sale |
6.09 |
1,786 |
10,877 |
64,350 |
| Brazzell Romulus K | SEE REMARKS |
May 31 '24 |
Sale |
6.09 |
2,002 |
12,192 |
89,471 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
May 31 '24 |
Sale |
6.09 |
7,392 |
45,017 |
278,923 |
0.48%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):